(Length of Discussion: 10 min)

Michael Cookson, MD, MMHC, talks with Alicia Morgans, MD on the newest developments in the AUA CRPC guidelines incorporating the results of the SPARTAN and PROSPER nmCRPC studies.  The intent of this guideline amendment is to update current management of index patient 1: asymptomatic non-metastatic CRPC.
Michael shares the need to revamp current guidelines which are shifting into advanced prostate cancer, the hormone-sensitive space, newly diagnosed disease, and not just focusing on castration-resistant disease but focusing on the whole management of the advanced metastatic disease.  

Biographies:
Michael S. Cookson, MD, MMHC, Professor, Chairman, Department of Urology, University of Oklahoma College of Medicine, Urologic Oncology 

Alicia Morgans, MD, MPH

Read the 2018 AUA Presentation on the Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018

First Presentation - SPARTAN: A Study of Apalutamide (ARN-509) in Men with Non-Metastatic Castration-resistant Prostate Cancer

First Presentation - PROSPER: Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)